Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VNDA - the official version of the 'poison pill' has been posted...
https://capedge.com/filing/1347178/0001193125-24-099263/VNDA-8A12B
Is anyone able to make sense of this legalese mumbo jumbo? Ahhh, the promiscuity of the legal profession...
VNDA - here's an 8K 'poison pill' challenge for you:
Flip-In Trigger
If an Acquiring Person obtains beneficial ownership of 10% or more of the Common Stock, then each Right will entitle the holder thereof to purchase, for the Exercise Price, a number of shares of Common Stock (or, in certain circumstances, cash, property or other securities of the Company) having a then-current market value of twice the Exercise Price.
Following the occurrence of an event set forth in preceding paragraph, all Rights that are or, under certain circumstances specified in the Rights Agreement, were beneficially owned by an Acquiring Person or certain of its transferees will be void.
Flip-Over Trigger
If, after an Acquiring Person obtains 10% or more of the Common Stock, (1) the Company merges into another entity, (2) an acquiring entity merges into the Company or (3) the Company sells or transfers more than 50% of its assets, cash flow or earning power, then each Right (except for Rights that have previously been voided as set forth above) will entitle the holder thereof to purchase, for the Exercise Price, a number of shares of Common Stock of the person engaging in the transaction having a then-current market value of twice the Exercise Price.
https://capedge.com/filing/1347178/0001193125-24-099263/VNDA-8A12B
Why no "Flip-Out Trigger"? lol...and we watch
VNDA - officially rejected the offer soon after the announcement...I'm certain 'Future Pak' is legit.
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-confirms-rejection-of-unsolicited-takeover-proposals-from-future-pak-302119534.html
https://www.futurepak.com/
This stock has been very good to me for several months...already got one .45 flip this morning and this news would seem to secure my $4 callwrites...still flippin
VNDA 5.00 (premarket) - Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
https://finance.yahoo.com/news/future-pak-confirms-proposal-acquire-103000446.html
VNDA 5.00 (premarket) - Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
https://finance.yahoo.com/news/future-pak-confirms-proposal-acquire-103000446.html
ELYM - nice trading. I was holding out for a dip down to 2.60pps and never established a position...c'est la vie
OMIC .427 - also adding here. The PRE 14A is filed and assuming they follow through with a Reverse Split...we could well be holding a $5pps or $10pps stock trading at 1/4 of cash...it'd be a first for me.
3. To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect, at the option of our Board of Directors, a reverse stock split of our common stock at a ratio between 1-for-10 to 1-for-30, inclusive, as determined by our Board of Directors in its sole discretion. We refer to this as the “Reverse Stock Split Proposal” or “Proposal 3.”
https://capedge.com/filing/1850906/0000950170-24-042294/OMIC-PRE14A
CPSS 7.86 - adding on this morning's news...
Consumer Portfolio Services Appoints Gateway to Lead Expanded Investor Relations Program
https://ih.advfn.com/stock-market/NASDAQ/consumer-portfolio-servi-CPSS/stock-news/93600064/consumer-portfolio-services-appoints-gateway-to-le
With Book Value $13+ and current quarter EPS .29 maybe this recent development can help wake the madding crowd?
IMMR 7.20 - rebuying a little here...the chart looks right (how much control can Eric Singer really have?) and the successful lawsuit vs. META makes IMMR kinda special.
VNDA 4.88 - Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/93593630/vanda-pharmaceuticals-fanapt-iloperidone-receives
VNDA 4.88 - Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/93593630/vanda-pharmaceuticals-fanapt-iloperidone-receives
XLO 1.38 - nice buy. I exited my last shares yesterday before close and will attempt to swing trade the momentum, shortterm. Longterm, I thought the recent news was pretty dynamic for a $1 biotech stock and may try to build a poke to just hang on?
XLO 1.25 - interesting development announcing a corroboration with GILD, sizeable upfront payment, and more importantly this:
Item 8.01. Other Events.
As previously disclosed, in connection with Xilio Development, Inc., a wholly-owned subsidiary of Xilio Therapeutics, Inc. (the “Company”), entering into an exclusive license agreement with Gilead Sciences, Inc. (“Gilead”), on March 27, 2024, the Company entered into a stock purchase agreement with Gilead pursuant to which the Company agreed to, among other things, initially issue and sell 6,860,223 shares (the “Gilead Shares”) of its common stock, $0.0001 par value per share (the “Common Stock”), to Gilead in a private placement at a purchase price of $1.97 per share, for an aggregate purchase price of approximately $13.5 million (the “Initial Gilead Private Placement”). The Initial Gilead Private Placement closed on March 28, 2024.
As of March 25, 2024, the Company had 27,613,263 shares of Common Stock outstanding. Following the issuance of the Gilead Shares upon the closing of the Initial Gilead Private Placement on March 28, 2024, the Company had 34,473,486 shares of Common Stock outstanding.
https://www.sec.gov/edgar/browse/?CIK=1840233&owner=exclude
I'm still bidding 1.20's in afterhours as I'm 100% certain GILD knows more than I do concerning this specific matter.
XLO 1.25 - (clarification) 8K released afterhours:
Item 8.01. Other Events.
As previously disclosed, in connection with Xilio Development, Inc., a wholly-owned subsidiary of Xilio Therapeutics, Inc. (the “Company”), entering into an exclusive license agreement with Gilead Sciences, Inc. (“Gilead”), on March 27, 2024, the Company entered into a stock purchase agreement with Gilead pursuant to which the Company agreed to, among other things, initially issue and sell 6,860,223 shares (the “Gilead Shares”) of its common stock, $0.0001 par value per share (the “Common Stock”), to Gilead in a private placement at a purchase price of $1.97 per share, for an aggregate purchase price of approximately $13.5 million (the “Initial Gilead Private Placement”). The Initial Gilead Private Placement closed on March 28, 2024.
As of March 25, 2024, the Company had 27,613,263 shares of Common Stock outstanding. Following the issuance of the Gilead Shares upon the closing of the Initial Gilead Private Placement on March 28, 2024, the Company had 34,473,486 shares of Common Stock outstanding.
https://www.sec.gov/edgar/browse/?CIK=1840233&owner=exclude
I'm still bidding 1.20's in afterhours as I'm 100% certain GILD knows more than I do concerning this specific matter.
XLO - what's your opinion of this new GILD collaboration...any meat on the bone there? XLO still qualifies as a near-cash play. I might re-enter on any dip to 1.20's at the close in anticipation of a likely gap up in Monday's premarket.
VNDA 4.05 - just sold some April19/$4 calls at .40
PSIX 2.45 - finally getting some love...still too cheap!
https://www.nasdaq.com/market-activity/stocks/psix/revenue-eps
NKTX 9.87 - the April19-$10-Call Option is currently bidding at $1.10. Their recent K filing showed $5+ cash remaining and they just secondaried at $10 which should put them well above $5+ cash per share accompanied by some upcoming inevitable touting...one can only hope the option premiums remain this high?
https://finance.yahoo.com/news/nkarta-announces-pricing-240-million-103000060.html
New and existing investors participated in the offering, including Adage Capital Partners LP, Boxer Capital, Commodore Capital, Cormorant Asset Management, an affiliate of Deerfield Management, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, Ridgeback Capital Investments, Samsara BioCapital, SR One, and a leading mutual fund.
NKTX 9.87 - the April19-$10-Call Option is currently bidding at $1.10. Their recent K filing showed $5+ cash remaining and they just secondaried at $10 which should put them well above $5+ cash per share accompanied by some upcoming inevitable touting...one can only hope the option premiums remain this high?
https://finance.yahoo.com/news/nkarta-announces-pricing-240-million-103000060.html
New and existing investors participated in the offering, including Adage Capital Partners LP, Boxer Capital, Commodore Capital, Cormorant Asset Management, an affiliate of Deerfield Management, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, Ridgeback Capital Investments, Samsara BioCapital, SR One, and a leading mutual fund.
OMIC .51 - filed their Q4 yesterday. Kinda blah imo...increasing revenue however miles away from any profit, didn't provide guidance, and looks like they're committed to their plan (no close-the-doors-cashout for an easy triple).
Interesting development I see in OMIC's very near future. OMIC must respond to the “Minimum Bid Price Requirement” by July 15, 2024.The company has noted that if they can't meet the $1.00 threshold, they would entertain a Reverse Split. A possible WIN-WIN for a plebian shareholder?? We can be sure management will try every trick in the book to get the pps above $1.00...or...effect an R/S which should be a positive as the strong cash position would remain the same and a consequent higher pps would be much more attractive to investors?
As previously disclosed, on July 17, 2023, the Company received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for the Company’s common stock had closed below $1.00 for the previous 30 consecutive business days (the “Minimum Bid Price Requirement”). In response, the Company filed an application to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. As a result of the Approval, the Company has been granted an additional 180-day compliance period, or until July 15, 2024, to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company’s common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day compliance period. If the Company fails to regain compliance during the additional compliance period, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company would have an opportunity to appeal the delisting determination to a Nasdaq Hearings Panel.
In connection with obtaining the Approval, the Company notified Nasdaq in writing of its intention to cure its deficiency in satisfying the Minimum Bid Price Requirement by effecting a reverse stock split prior to July 15, 2024, if necessary.
The Company intends to continue to actively monitor the Minimum Bid Price Requirement and, as appropriate, will consider available options to resolve any deficiencies and regain compliance.
https://capedge.com/filing/1850906/0000950170-24-005804/OMIC-8K
VNDA / GERN - I was going to respond with GERN is ripe for a secondary while VNDA is not...guess my brain was working too slowly? lol
My point was about the extreme high risk associated with GERN while so many biobusts such as VNDA are trading well below cash and also hold reward value while sustaining a very low risk.
ELYM - strange that they announce they're buying something but don't say what lol? Approx. $4 cash with a super clean Balance Sheet. I stuck in a low-ball order...will watch.
https://capedge.com/filing/1768446/0001193125-24-070333/ELYM-8K/file/2
GERN 3.18??? / VNDA 3.75 - I'm just not feeling it with GERN? Extreme risk of capital and after, by far, the best news since you've been touting GERN...can't seem to get out of it's own way?
VNDA sitting on a pile of cash, monthly revenues, and two PDUFA dates upcoming. Preservation-of-Capital appears to be an absolute no-brainer between these two stocks, VNDA vs GERN.
ELYM 2.81 - an acquisition afterhours?? Only vague details so far...are you seeing anything?
PSIX 2.12 - posts .36 quarterly eps...very impressive for a $2 stock...will add in weakness:
Dino Xykis, Chief Executive Officer and Chief Technical Officer, commented, “While we were unable to reach the topline revenue goals we set out for ourselves at the beginning of the year due to the unforeseen headwinds of the UFLPA and overall market conditions, we are pleased with what we were able to achieve by increasing margins and overall profitability, an accomplishment we would not have been able to achieve without the full support of every individual here at Power Solutions.”
Xykis continued, “While some of these topline pressures are expected to continue into 2024, we expect strong growth from the power systems end market to help drive our outlook for the upcoming year.”
https://www.otcmarkets.com/stock/PSIX/news/story?e&id=2796621
FEIM - one of the uglier reports imo. I always admired poster "10bagger"s propensity to bail immediately when he saw anything amiss...exactly what I did in afterhours yesterday. Who can trust them again into their next filingS, plural...
IMMR 8.16 - exited my position this morning. Still can't wrap my head around reported yearly revenue of $34M while touting profits of $43M...did they plant a money tree?...find a few obscure 10-bagger stocks? From the horse's mouth:
Eric Singer, Chairman & CEO, stated, "2023 was a year of steady execution and accomplishment for Immersion as we maintained our efforts to enforce our intellectual property, renew license deals, and thoughtfully allocate capital. We returned $15.7 million to shareholders via buybacks and dividends during the year while also increasing our stockholder’s equity to $183.1 million, or $5.81 per share, as of December 31, 2023. This is an increase of over $27.4 million from $157.7 million, or $4.89 per share, at the end of 2022."
https://finance.yahoo.com/news/immersion-corporation-reports-fourth-quarter-210500981.html
FEIM 10.75 - holding a few into earnings...glass-half-full - they were too busy with orders to rush a filing?
GENC 15.92 - also adding here...primed for institutions to take hold...we shall see?
CPSS 8.36 - taking some here...they should be filing Q4 any day now. Looking for BV of approx. $12.50 and yearly EPS of approx. $2.00.
CPSS getting no love...
https://www.nasdaq.com/market-activity/stocks/cpss/revenue-eps
GEOS 11.95 - taking a few here while writing the "April$12.50 Call" at .60...a 5% premium (for 6 weeks) with another possible 5% at pps12.50.
IMMR 7.15 - can you cite any examples of "the Singer stink", tia?
IMMR 7.40 - trying to hold on for $8's...we still don't know what those recent exceptional numbers are all about?
AMLX 2.97 (down 16 bucks) - biobust dujour on a failed Phase 3? Showing approx. $6 cash per share...should be an excellent trader for awhile...
IMMR 7.05 - I added in afterhours on the surprise numbers...the longterm perception of winning a lawsuit against META.....
IMMR 6.77 - they should've released that positive tidbit inside the upcoming K-filing imo, also overdue imo. I'm holding a small position into earnings...might get a chance to accumulate cheaper in the likelihood they post some shortterm crummy numbers?
TLIS - taking a closer look, I guess the small float is a plus but still too confusing for my taste?
RPHM is very similar maneuvering back to a shell status...I've been trading RPHM.